Related Experiment Videos
Raynaud's phenomenon in mixed connective tissue disease
Thomas Grader-Beck1, Fredrick M Wigley
1Division of Rheumatology, Johns Hopkins School of Medicine, 5200 Eastern Avenue, Suite 4100, Baltimore, MD 21224, USA.
Rheumatic Diseases Clinics of North America
|August 9, 2005
Summary
Raynaud's phenomenon is a common early sign of mixed connective tissue disease (MCTD), indicating systemic vasculopathy. Early detection via nailfold capillaroscopy and targeted therapies are crucial for managing MCTD-associated Raynaud's.
Area of Science:
- Rheumatology
- Vascular Medicine
Background:
- Raynaud's phenomenon is a prevalent symptom in mixed connective tissue disease (MCTD), often presenting as the initial clinical manifestation.
- It signifies a systemic vasculopathy marked by intimal fibrosis and vessel obliteration, potentially leading to visceral complications like pulmonary hypertension.
Purpose of the Study:
- To summarize the clinical significance of Raynaud's phenomenon in MCTD.
- To highlight diagnostic tools and therapeutic strategies for managing this condition.
Main Methods:
- Review of literature on Raynaud's phenomenon in MCTD.
- Analysis of the association with anti-U1-RNP antibodies.
- Discussion of diagnostic utility of nailfold capillaroscopy.
- Overview of current and novel therapeutic approaches.
Main Results:
- Raynaud's phenomenon is strongly associated with MCTD and anti-U1-RNP antibodies across various rheumatic diseases.
- Nailfold capillaroscopy is a valuable diagnostic aid for identifying patients at risk for MCTD.
- Therapeutic goals include reducing attack frequency, preventing digital ulcers, and limiting vascular damage.
Conclusions:
- Raynaud's phenomenon is a key indicator of MCTD, reflecting underlying systemic vasculopathy.
- Effective management involves early diagnosis and a combination of traditional and novel vascular therapies to prevent complications.